In preclinical xenograft studies of NSCLC that harbored ALK rearrangements, WX-0593 demonstrated potent antitumor activity against both crizotinib-sensitive and crizotinib-resistant tumors. The gene discussed is ALK; the disease is non-small cell lung carcinoma.